NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

ATYR

Atyr Pharma Inc

May 30 • 04:00PM ET

4.47

Dollar change +0.21
Percentage change 5.05	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN SRPT ALNY NBIX IONS FOLD BLUE PTCT CSL

| Held by: VTI VXF IWC DFAS DFSU DFAC AVSC DFUS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.81	Insider Own	3.31%	Shs Outstand	89.00M	Perf Week	17.63%
Market Cap	397.85M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	0.05%	Shs Float	86.06M	Perf Month	28.82%
Income	-63.41M	PEG	-	EPS next Q	-0.18	Inst Own	69.43%	Short Float	14.74%	Perf Quarter	13.02%
Sales	0.00M	P/S	-	EPS this Y	23.15%	Inst Trans	12.38%	Short Ratio	8.53	Perf Half Y	43.27%
Book/sh	0.84	P/B	5.30	EPS next Y	14.31%	ROA	-60.25%	Short Interest	12.68M	Perf Year	149.72%
Cash/sh	0.86	P/C	5.21	EPS next 5Y	-	ROE	-79.51%	52W Range	1.42 - 4.66	Perf YTD	23.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	34.28%	ROI	-73.10%	52W High	-4.08%	Beta	0.86
Dividend TTM	-	Quick Ratio	7.79	Sales past 5Y	429.49%	Gross Margin	-	52W Low	214.79%	ATR (14)	0.29
Dividend Ex-Date	-	Current Ratio	7.79	EPS Y/Y TTM	10.73%	Oper. Margin	-	RSI (14)	73.85	Volatility	2.93% 5.15%
Employees	59	Debt/Eq	0.17	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	18.55
Option/Short	Yes / Yes	LT Debt/Eq	0.16	EPS Q/Q	26.62%	Payout	-	Rel Volume	1.15	Prev Close	4.26
Sales Surprise	-	EPS Surprise	10.99%	Sales Q/Q	-100.00%	Earnings	May 07 AMC	Avg Volume	1.49M	Price	4.47
SMA20	25.80%	SMA50	34.32%	SMA200	45.52%	Trades		Volume	1,715,311	Change	5.05%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-18-25	Initiated	Leerink Partners	Outperform	$16
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Oct-04-24	Initiated	Wells Fargo	Overweight	$17
Sep-05-24	Initiated	Jefferies	Buy	$9
Jul-05-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-12-21	Initiated	RBC Capital Mkts	Outperform	$22
Sep-21-21	Initiated	Piper Sandler	Overweight	$19
May-10-21	Initiated	Laidlaw	Buy	$18
Aug-17-20	Upgrade	H.C. Wainwright	Neutral → Buy	$13
Mar-04-20	Initiated	ROTH Capital	Buy	$15
Mar-02-20	Initiated	Oppenheimer	Outperform	$8
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-07-17	Initiated	Piper Jaffray	Overweight	$7
Dec-13-16	Downgrade	JP Morgan	Overweight → Neutral
Dec-16-15	Initiated	Citigroup	Neutral
Jun-01-15	Initiated	JP Morgan	Overweight	$44
Jun-01-15	Initiated	Citigroup	Buy	$32

Show Previous Ratings

May-21-25 11:21AM	aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential (Insider Monkey) +7.45%
May-20-25 08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-19-25 08:00AM	aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference (GlobeNewswire) +5.20%
May-16-25 04:01PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.00%
May-14-25 08:00AM	aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis (GlobeNewswire) -8.46%
08:32AM	Loading…
May-09-25 08:32AM	Is aTyr Pharma, Inc. (ATYR) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-07-25 04:01PM	aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update (GlobeNewswire) +5.70%
Apr-29-25 08:00AM	aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Apr-03-25 08:00AM	aTyr Pharma to Participate in April Investor Conferences (GlobeNewswire) -5.74%
Mar-27-25 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
12:27PM	Is aTyr Pharma (ATYR) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-26-25 08:00AM	aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise (GlobeNewswire) -7.16%
Mar-19-25 09:40AM	Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-14-25 03:11AM	aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Mar-13-25 04:01PM	aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update (GlobeNewswire) +12.39%
04:00PM	Loading…
Mar-12-25 04:00PM	aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine (GlobeNewswire) +15.64%
Mar-06-25 04:02PM	aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary Sarcoidosis (GlobeNewswire) +10.39%
Mar-04-25 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results (GlobeNewswire) -8.18%
Feb-24-25 08:00AM	aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire) -11.34%
Jan-29-25 08:00AM	aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference (GlobeNewswire)
Dec-17-24 08:00AM	aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-24 04:00PM	aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors (GlobeNewswire)
Dec-10-24 08:00AM	aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary Sarcoidosis (GlobeNewswire) -6.80%
Dec-09-24 08:00AM	aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis (GlobeNewswire) +5.06%
Nov-15-24 08:00AM	aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis (GlobeNewswire) -8.93%
Nov-07-24 04:01PM	aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update (GlobeNewswire)
Oct-31-24 08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-14-24 08:00AM	aTyr Pharma to Present at the LD Micro Main Event XVII in October (Newsfile)
Oct-08-24 08:00AM	aTyr Pharma's Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting (GlobeNewswire)
Oct-02-24 08:00AM	aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal (GlobeNewswire)
08:00AM	Loading…
Aug-21-24 08:00AM	aTyr Pharma to Participate in September Investor Conferences (GlobeNewswire)
Aug-13-24 04:00PM	aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update (GlobeNewswire) +6.32%
Aug-06-24 08:00AM	aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations (GlobeNewswire)
Jul-30-24 08:00AM	aTyr Pharma Announces Research Study with Stanford Medicine (GlobeNewswire) -6.60%
Jul-22-24 08:00AM	aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis (GlobeNewswire) +13.41%
Jun-18-24 09:40AM	Is aTyr Pharma (ATYR) Outperforming Other Medical Stocks This Year? (Zacks) -6.78%
Jun-10-24 10:52AM	ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2023 (InvestorPlace)
Jun-05-24 03:17PM	Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025 (InvestorPlace)
Jun-03-24 08:00AM	aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from LIFE to ATYR (GlobeNewswire) +6.94%
May-24-24 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-15-24 07:00AM	aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference (GlobeNewswire) +5.22%
May-14-24 08:00AM	aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary Sarcoidosis (GlobeNewswire) +7.06%
May-06-24 08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-02-24 09:58PM	LIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:15PM	Atyr Pharma: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update (GlobeNewswire)
Apr-01-24 08:00AM	aTyr Pharma to Participate in April Investor Conferences (GlobeNewswire)
Mar-26-24 02:19PM	3 Penny Stocks That Could Be Multibaggers in the Making: March Edition (InvestorPlace)
Mar-15-24 01:33PM	aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript (Insider Monkey) +22.84%
11:30AM	Q4 2023 aTyr Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
11:01AM	aTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress (GuruFocus.com)
Mar-14-24 08:56PM	LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023 (InvestorPlace)
04:16PM	Atyr Pharma: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update (GlobeNewswire)
Feb-28-24 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results (GlobeNewswire) -5.00%
Feb-21-24 08:00AM	aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT Clinical Trial Participants (GlobeNewswire)
Jan-29-24 08:00AM	aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity (GlobeNewswire)
Jan-18-24 08:00AM	aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor (GlobeNewswire)
Nov-13-23 08:00AM	aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023 (GlobeNewswire)
Nov-09-23 04:07PM	Atyr Pharma: Q3 Earnings Snapshot (Associated Press Finance) -5.74%
04:00PM	aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
Nov-01-23 08:00AM	aTyr Pharma to Present at November Investor Conferences (GlobeNewswire)
Oct-31-23 08:00AM	aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT Study of Efzofitimod in Patients with SSc-ILD (GlobeNewswire)
Sep-11-23 08:00AM	aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes (GlobeNewswire)
Aug-30-23 09:35AM	Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE) (Zacks)
Aug-24-23 08:00AM	aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-09-23 05:30PM	Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:29PM	Atyr Pharma: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
Jul-20-23 07:30AM	aTyr Pharma, Inc. (NASDAQ:LIFE) is a favorite amongst institutional investors who own 56% (Simply Wall St.)
Jun-28-23 07:00AM	7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023 (InvestorPlace)
Jun-22-23 08:00AM	European Commission Grants Orphan Drug Designation for aTyr Pharmas Efzofitimod for Treatment of Systemic Sclerosis (GlobeNewswire)
Jun-20-23 08:00AM	aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference (GlobeNewswire)
Jun-09-23 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-23 08:00AM	aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023) (GlobeNewswire)
May-25-23 08:00AM	aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-22-23 08:00AM	aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference (GlobeNewswire)
07:33AM	Weekly biotech pulse: Sana, aTyr, Theseus to release fresh data (Investing.com)
May-13-23 08:06AM	aTyr Pharma Independent Director Acquires 25% More Stock \ (Simply Wall St.)
May-11-23 04:00PM	aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-10-23 06:11AM	aTyr Pharma (NASDAQ:LIFE) investors are sitting on a loss of 89% if they invested five years ago (Simply Wall St.) +6.10%
May-09-23 05:15PM	Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:12PM	Atyr Pharma: Q1 Earnings Snapshot (AP Finance)
04:00PM	aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
May-07-23 04:00AM	3 Stocks and Cryptos With the Highest Potential Returns (InvestorPlace)
May-05-23 02:24PM	7 Hot Growth Stocks Poised to Triple in 2023 (InvestorPlace)
Apr-17-23 08:00AM	aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting (GlobeNewswire)
Mar-30-23 08:00AM	aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases (GlobeNewswire)
Mar-28-23 10:45AM	2 Strong Buy Penny Stocks With Over 200% Upside on the Horizon (TipRanks) +9.64%
Mar-23-23 07:10AM	Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation (Simply Wall St.)
Mar-21-23 08:00AM	aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution (GlobeNewswire)
Mar-20-23 08:00AM	aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies (GlobeNewswire)
Mar-09-23 05:15PM	Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.18%
04:00PM	aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update (GlobeNewswire)
Mar-08-23 08:00AM	aTyr Pharma to Present at March Investor Conferences (GlobeNewswire)
Mar-02-23 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results (GlobeNewswire)
Mar-01-23 08:00AM	aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application (GlobeNewswire)
Feb-17-23 12:00PM	Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know (Zacks)
Feb-10-23 05:21AM	With 37% stake, aTyr Pharma, Inc. (NASDAQ:LIFE) seems to have captured institutional investors' interest (Simply Wall St.)
Feb-09-23 08:00AM	aTyr Pharma Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -7.56%

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gross Jane A	Director	Mar 17 '25	Buy	4.00	3,750	15,000	9,750	Mar 17 07:07 PM
Broadfoot Jill Marie	Chief Financial Officer	Feb 04 '25	Sale	3.78	1,254	4,740	31,763	Feb 04 06:14 PM
DENYES NANCY	General Counsel	Feb 04 '25	Sale	3.78	899	3,398	26,555	Feb 04 06:11 PM
SCHIMMEL PAUL	Director	Jul 24 '24	Buy	1.93	52,300	101,038	413,023	Jul 24 05:29 PM
SCHIMMEL PAUL	Director	Jul 22 '24	Buy	1.74	41,052	71,500	354,075	Jul 24 05:29 PM
SCHIMMEL PAUL	Director	Jul 23 '24	Buy	1.82	6,648	12,075	360,723	Jul 24 05:29 PM
DENYES NANCY	General Counsel	Jun 05 '24	Buy	1.86	5,000	9,276	22,267	Jun 06 08:26 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATYR

Atyr Pharma Inc

Upgrade your FINVIZ experience